Skip to content
Search

Latest Stories

Smoking rates at record low, pharmacies seek funding to turbocharge reduction

Smoking rates at record low, pharmacies seek funding to turbocharge reduction

Community pharmacies urge the government to reverse cuts to local public health budgets and invest in stop smoking services

The Office for National Statistics (ONS) has released new data revealing that adult smoking rates in the UK have fallen to their lowest levels on record.

In 2023, only 11.9 per cent of adults aged 18 and over—approximately 6 million people—reported smoking cigarettes, marking the lowest proportion of smokers since the Annual Population Survey (APS) began in 2011.


Since 2011, the proportion of smokers has decreased by 8.3 percentage points from 20.2 per cent.

However, this change was not statistically significant when compared to the previous year’s rates, which was 12.9 per cent in 2022.

Among age groups, those aged 25 to 34 years had the highest smoking prevalence at 14.0 per cent in 2023.

Notably, the 18 to 24 age group experienced the largest reduction in smoking rates, dropping by 15.9 percentage points from 25.7 per cent in 2011 to 9.8per cent in 2023.

Commenting on the new ONS statistics, Paul Rees, CEO of the National Pharmacy Association (NPA), highlighted the importance of community pharmacies in combating smoking.

"For decades, community pharmacies across the UK have been instrumental in the fight against smoking. Through their locally commissioned services they have supported hundreds of thousands of people to help quit.

"It is good to see a reduction in levels of smoking. Smoking still remains of the biggest causes of ill health in our communities,” he said.

Rees noted, however, that cuts to local public health budgets by the central government have resulted in the decommissioning of some vital stop smoking services in community pharmacies.

"If we are to turbocharge this reduction in the rates of smoking, we need to reverse these cuts and invest in these services in our community pharmacies.

"Pharmacies should also be able to provide a nationally commissioned walk in smoking cessation service, which would end the postcode lottery for accessing support,” he said.

Rise in e-cigarette use

In contrast, e-cigarette use in Great Britain has risen, as indicated by the ONS data.

In 2023, around 5.1 million adults aged 16 and over (9.8 per cent) in Great Britain reported using e-cigarettes either daily or occasionally, based on the Opinions and Lifestyle Survey (OPN).

Daily e-cigarette usage among this demographic rose to 5.9 per cent, up from 5.2 per cent in 2022, while occasional use increased to 3.9 per cent, compared to 3.5per cent the previous year.

E-cigarette use was notably high among younger individuals, with 15.8 per cent of those aged 16 to 24 using them either daily or occasionally.

Regional variations in smoking prevalence were observed: 11.6 per cent in England, 12.6 per cent in Wales, 13.5 per cent in Scotland, and 13.3per cent in Northern Ireland.

Men continued to smoke more than women, with 13.7 per cent of men (approximately 3.4 million) and 10.1 per cent of women (around 2.6 million) identifying as current smokers in 2023.

The data also revealed disparities in smoking prevalence based on economic status.  Unemployed individuals had a higher proportion of current smokers (19.7 per cent), compared with those in paid employment (11.4 per cent) and those classified economically inactive (12.2 per cent).

Additionally, smoking rates were notably higher in routine and manual occupations (20.2 per cent) compared to managerial and professional roles (7.9 per cent).

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less